Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: Extra Pale who wrote (2235)	3/24/2005 2:11:18 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 12215

>> Been whacked by four "postive spin" trial failures this month << Ouch. Ouch, ouch, ouch.

To: Extra Pale who wrote (2235)	3/24/2005 5:38:20 PM
From: zeta1961	Respond to of 12215

Guilford announcement reads great on the surface - but why are they halting trial, what's rationale for lower dose? It sounds like it over-sedated people and probably led to respiratory depression necessitating either supplemental oxygen at the least or intubation at the most extreme..I'm sorry you got hit with this..imho(and many intensivists',nurses') midazolam was/is the best thing since the proverbial sliced bread..or ether!..tough to match it's ease of use, , water soluble(doesn't kill veins) sedation, anti-epileptic properties, quick action(they don't state how midazolam scored in comparison)..we've used it like H20..I've received it once pre-sinus surgery..best thing the poor anesthesia intern could have done for himself..I was driving him nuts..by the time the surgeon came, I was a smiling, well behaved ICU-nurse patient.. I'm not minimizing the loss of having a drug fail against it because one does have to watch for respiratory depression..but truly a tough one to beat on many fronts.. Zeta